Abstract: The present invention generally relates to antibody combinations and uses thereof.

Abstract: The present invention generally relates to combinations for use in therapeutic systems and antibody dosage regimens, and uses thereof. Also described herein is a model for predicting if a therapeutic antibody binding to a human target will be associated with a tolerability issue in connection with intravenous administration and/or for predicting if pre-treatment, altered administration route or modification of the antibody can prevent a tolerability issue associated with intravenous administration to a human of the therapeutic antibody. The model comprises administering the antibody intravenously or intraperitoneally to mice and observing the mice immediately after the administration for any transient display of the macroscopic symptoms isolation and decreased activity.

Abstract: Described are anti-LILRB3 antibody molecules, such as agonistic anti-LILRB3 antibody molecules for use in treatment of graft rejection or autoimmunity via reprograming of human myeloid cells. Described are also specific anti-LILRB3 antibody molecules and use of such antibody molecules in medicine, for example in treatment of graft rejection, autoimmune disorders or inflammatory disorders.

Abstract: Described is the sequential administration of first a Treg depleting antibody mole-cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De-scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.

Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.

Abstract: Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein.

Abstract: Described are novel antagonistic antibody molecules that specifically bind to TNFR2 on a target cell and thereby block TNF-? binding to TNFR2 and block TNFR2 signaling, wherein the antibody molecules also bind to Fc receptors via the Fc region. Also described is the use of such antibody molecules in treatment of cancer or infections caused by intracellular pathogens.

Abstract: Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.

Abstract: Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-? from binding to the TNFR2. Also described is the use of such antibody molecules in medicine, i.a, in treatment of cancer or chronic inflammatory diseases.

Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.

Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIb via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an Fc?RIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.

Abstract: The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands: providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand; providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.

Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, together with further anti-cancer agents, and compositions thereof, for use in the treatment of cancer.

Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.

Abstract: Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

Abstract: The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands; providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand: providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.

Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, for use in the treatment of cancer in patients who have previously been treated for cancer and either not responded to said treatment or have previously responded to said treatment and subsequently relapsed.

Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, together with further anti-cancer agents, and compositions thereof, for use in the treatment of cancer.

Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.